Real-time Estimate
Cboe BZX
09:38:22 2024-05-20 am EDT
|
5-day change
|
1st Jan Change
|
39.11
USD
|
+18.17%
|
|
+2.62%
|
+20.08%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,960
|
4,164
|
2,816
|
2,786
|
2,080
|
2,538
|
-
|
-
|
Enterprise Value (EV)
1 |
2,986
|
3,393
|
2,474
|
2,947
|
1,487
|
2,078
|
2,278
|
2,248
|
P/E ratio
|
-11.2
x
|
-9.19
x
|
-5.36
x
|
-4.9
x
|
-3.29
x
|
-5.76
x
|
-7.29
x
|
-15.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.64
x
|
10.9
x
|
5.23
x
|
3.99
x
|
2.22
x
|
3.78
x
|
3.79
x
|
3.26
x
|
EV / Revenue
|
9.73
x
|
8.91
x
|
4.59
x
|
4.22
x
|
1.59
x
|
3.1
x
|
3.4
x
|
2.88
x
|
EV / EBITDA
|
-
|
-12
x
|
-7.97
x
|
-9.25
x
|
-7.33
x
|
-15.4
x
|
-26.7
x
|
104
x
|
EV / FCF
|
-26.6
x
|
-16
x
|
-8.85
x
|
-7.58
x
|
-7.96
x
|
-8.71
x
|
-27.6
x
|
27.3
x
|
FCF Yield
|
-3.76%
|
-6.25%
|
-11.3%
|
-13.2%
|
-12.6%
|
-11.5%
|
-3.63%
|
3.66%
|
Price to Book
|
5.01
x
|
8.36
x
|
1,952
x
|
-7.89
x
|
-2.55
x
|
-2.36
x
|
-2.19
x
|
-2.33
x
|
Nbr of stocks (in thousands)
|
61,631
|
68,236
|
70,698
|
72,991
|
75,463
|
76,697
|
-
|
-
|
Reference price
2 |
48.03
|
61.03
|
39.83
|
38.17
|
27.56
|
33.10
|
33.10
|
33.10
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/22/22
|
2/21/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
307
|
380.8
|
538.6
|
698.8
|
937.8
|
671.2
|
669.7
|
779.3
|
EBITDA
1 |
-
|
-282.7
|
-310.3
|
-318.6
|
-202.9
|
-134.7
|
-85.34
|
21.68
|
EBIT
1 |
-241.2
|
-326.2
|
-374.4
|
-447.4
|
-439.5
|
-274.7
|
-192.6
|
-45.26
|
Operating Margin
|
-78.56%
|
-85.66%
|
-69.52%
|
-64.03%
|
-46.86%
|
-40.93%
|
-28.76%
|
-5.81%
|
Earnings before Tax (EBT)
1 |
-239.9
|
-402.9
|
-518.3
|
-587.5
|
-696.1
|
-466.8
|
-392.7
|
-206
|
Net income
1 |
-251.6
|
-438.2
|
-523.9
|
-559
|
-626.6
|
-448.7
|
-369.3
|
-186.5
|
Net margin
|
-81.95%
|
-115.07%
|
-97.27%
|
-80%
|
-66.81%
|
-66.85%
|
-55.15%
|
-23.93%
|
EPS
2 |
-4.270
|
-6.640
|
-7.430
|
-7.790
|
-8.370
|
-5.746
|
-4.538
|
-2.124
|
Free Cash Flow
1 |
-112.4
|
-211.9
|
-279.5
|
-388.7
|
-186.9
|
-238.5
|
-82.67
|
82.33
|
FCF margin
|
-36.61%
|
-55.65%
|
-51.9%
|
-55.62%
|
-19.92%
|
-35.53%
|
-12.34%
|
10.56%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
379.84%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/22/22
|
2/21/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
165.2
|
148.7
|
165.5
|
217.1
|
167.4
|
220.4
|
213.8
|
196.6
|
307.1
|
210.1
|
158.7
|
143.7
|
158.2
|
117.6
|
131.8
|
EBITDA
|
-
|
-60.21
|
-
|
-
|
-
|
-74.79
|
-158.5
|
-
|
86.52
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-84.73
|
-86.52
|
-92.36
|
-68.19
|
-200.3
|
-117.6
|
-209.5
|
-118.2
|
5.82
|
-45.45
|
-72.87
|
-97.22
|
-82.18
|
-62.2
|
-51.4
|
Operating Margin
|
-51.28%
|
-58.17%
|
-55.8%
|
-31.4%
|
-119.67%
|
-53.37%
|
-98.01%
|
-60.11%
|
1.9%
|
-21.63%
|
-45.93%
|
-67.67%
|
-51.93%
|
-52.9%
|
-39%
|
Earnings before Tax (EBT)
1 |
-138.6
|
-121.9
|
-148.7
|
-127.2
|
-189.7
|
-135
|
-237.5
|
-166.6
|
-157.1
|
-84.7
|
-111.8
|
-139.2
|
-139.6
|
-101.4
|
-120.9
|
Net income
1 |
-143.3
|
-126.7
|
-152.1
|
-109.3
|
-170.9
|
-139
|
-198.9
|
-133
|
-155.8
|
-91.58
|
-101.8
|
-128.1
|
-126.2
|
-76.65
|
-70.65
|
Net margin
|
-86.71%
|
-85.2%
|
-91.88%
|
-50.35%
|
-102.08%
|
-63.05%
|
-93.02%
|
-67.64%
|
-50.74%
|
-43.58%
|
-64.18%
|
-89.15%
|
-79.77%
|
-65.2%
|
-53.6%
|
EPS
2 |
-2.030
|
-1.780
|
-2.130
|
-1.530
|
-2.350
|
-1.880
|
-2.660
|
-1.760
|
-2.060
|
-1.200
|
-1.265
|
-1.666
|
-1.675
|
-1.358
|
-1.200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/22/22
|
5/3/22
|
8/4/22
|
10/27/22
|
2/21/23
|
4/27/23
|
8/3/23
|
10/26/23
|
2/29/24
|
4/25/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
25.8
|
-
|
-
|
161
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
771
|
342
|
-
|
593
|
461
|
260
|
290
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.5054
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-112
|
-212
|
-280
|
-389
|
-187
|
-239
|
-82.7
|
82.3
|
ROE (net income / shareholders' equity)
|
-53.2%
|
-81.4%
|
-217%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-18.3%
|
-22.9%
|
-25.3%
|
-30.7%
|
-23.4%
|
-32.1%
|
-22.4%
|
12.4%
|
Assets
1 |
1,372
|
1,916
|
2,073
|
1,822
|
2,676
|
1,398
|
1,649
|
-1,504
|
Book Value Per Share
2 |
9.600
|
7.300
|
0.0200
|
-4.840
|
-10.80
|
-14.00
|
-15.10
|
-14.20
|
Cash Flow per Share
2 |
-1.680
|
-2.940
|
-3.570
|
-4.970
|
-2.120
|
-2.570
|
-3.410
|
-
|
Capex
1 |
13.8
|
17.8
|
28.2
|
32
|
28.4
|
29
|
31
|
28.5
|
Capex / Sales
|
4.48%
|
4.69%
|
5.24%
|
4.58%
|
3.03%
|
4.32%
|
4.63%
|
3.66%
|
Announcement Date
|
3/2/20
|
2/25/21
|
2/22/22
|
2/21/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
33.1
USD Average target price
29.5
USD Spread / Average Target -10.86% Consensus |
1st Jan change
|
Capi.
|
---|
| +20.08% | 2.54B | | +9.42% | 115B | | +11.84% | 106B | | -2.47% | 21.96B | | -14.15% | 21.87B | | -5.29% | 19.21B | | -4.16% | 18.08B | | -38.29% | 17.71B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|